Skip to content

Labor Scale Versus WHO Partograph for Management of Labor (ScaLP)

Labor Scale Versus WHO Partograph for Management of Spontaneous Labor in Primigravidae (ScaLP): A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05341076
Acronym
ScaLP
Enrollment
206
Registered
2022-04-22
Start date
2022-08-01
Completion date
2023-09-01
Last updated
2022-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dystocia

Keywords

Labor scale, Partograph, Spontaneous labor, Primigravida

Brief summary

The current study aims at evaluating the impact of the implementation of the labor scale, in comparison to the standard WHO partograph, in the management of primiparous women, including CD rate, maternal and neonatal outcomes of labor.

Detailed description

Since the procedure was first introduced to clinical practice, Cesarean delivery (CD) has significantly contributed to peripartum maternal and fetal safety when appropriately indicated. Nevertheless, CD rate has significantly increased over the last two decades without parallel improvement in maternal or neonatal outcomes. Globally, one out of three pregnancies would be delivered by CD, resulting in growing surgical, obstetric and financial burden. Over years, long-term sequelae of current CD rate have become evident such as increased incidence of placenta accreta spectrum and exponential rise in CD trend, since 90% of women who had CD are susceptible to CD in future pregnancies. These concerns have triggered a global act to control CD rates within the margins of safe obstetric practice. The most common indication of CD is labor dystocia. However, the definition of labor dystocia is inconsistent, and standardization of diagnosis has been heavily investigated. The WHO partograph was established at the end of the last century to serve as a tool to recognize labor dystocia and has been universally accepted to verify CD decision However, a cochrane review by Lavender et al. revealed that role of WHO partograph, in improving clinical outcomes, is lacking. In addition, there is no evidence that any published modification of the current partograph is superior to another. The labor scale, a novel alternative to the classic partograph, was first introduced to literature in 2014. The tool was designed based on evidence-based guidelines and integrates both diagnosis and interventions to manage labor dystocia. Initial data showed that labor scale contributed to decreased incidence of CD and oxytocin administration. However, further studies are required to verify these results.

Interventions

PROCEDUREAmniotomy

Amniotomy, artificial rupture of membranes, is done with an initial delay of labor (in partograph: extension beyond the alert line, in labor scale: when progress reaches the membrane line)

DRUGOxytocin

oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)

PROCEDURECesarean Section

Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

Pregnant women aged 18 to 45 years old with the following criteria: nulliparous, had been pregnant for 37 to 41 weeks with a singleton viable fetus, and vertex presented, and with estimated fetal weights between 2,500 and 4,500 g.

Exclusion criteria

Women with following criteria will be excluded: significant maternal medical or surgical comorbidity, previous uterine scar

Design outcomes

Primary

MeasureTime frameDescription
Successful vaginal delivery (reporting of whether labor ends in vaginal delivery or Cesarean Section. In case of CS, the indication will be reported)Duration of labor (maximum 24 hours from onset of labor)The proportion who delivered vaginal versus those indicated for Cesarean Section for labor dystocia

Secondary

MeasureTime frameDescription
Primary postpartum hemorrhageWithin 24 hours of deliveryPrimary postpartum hemorrhage is defined as estimated blood loss \> 500 ml following delivery and within 24 hours postpartum
Maternal fever/postpartum infectionsWithin 24 hours of deliveryThis is indicated by a single temperature at or above 38.0 c or 2 measurements at or above 37.5 c.
Intrapartum fetal distressDuration of labor (maximum 24 hours)This criterion is met if cardiotocography shows signs consistent with pathological tracing as defined by NICE guidelines (persistent late or variable decelerations, prolonged bradaycardia or sinusoidal rhythm)
Birth injuries of the newbornThe length of neonatal hospital stay (anticipated duration: 72 hours)Presence of bony fractures, cephalhematoma, or intracranial hemorrhage as evident by physical examination of the newborn
Intrapartum maternal birth injuriesDuration of labour and hospital stay (anticipated duration: 72 hours)This is assessed clinically at the time of labor, and includes the extent of vaginal and perineal traumas and type of repair
Duration of labor in hoursDuration of labor (maximum 24 hours)This starts from the onset of active labor (3 cm or more of cervical dilation) till actual delivery
Incidence of oxytocin useDuration of labor (maximum duration: 24 hours)Incidence of administration of intravenous oxytocin during labor for labor augmentation
Incidence of instrumental deliveryDuration of labor (maximum duration: 24 hours)Instrumental delivery includes forceps and ventouse deliveries
Neonatal distress asphyxiaThe length of stay in hospital/neonatal intensive care unit (anticipated duration: 72 hours)This is indicated by 1 and 5 minutes APGAR score, resuscitation event, umbilical artery pH, admission to neonatal intensive care unit, length of stay and any further medical complications

Countries

Egypt

Contacts

Primary ContactSherif Shazly, MSc
sherif.shazly.mogge@gmail.com+4407554480388
Backup ContactMohamed Abuelazm
mohamed.abuelazm.mogge@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026